Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

BENCHMARKING A ROBUST, HUMAN-RELEVANT PANCREATIC MICROTISSUE PLATFORM FOR METABOLIC DRUG DISCOVERY AND T2D DISEASE MODELING

Objective

Type 2 Diabetes (T2D) affects 537 million adults globally. The T2D drug market exceeds 50 billion USD annually, with GLP-1 receptor agonists as the fastest-growing class. Developing these drugs requires testing compounds on pancreatic beta cells, yet current models fail: rodent islets differ from human islets in architecture and receptor expression, contributing to a 92% clinical failure rate. Donor islets are scarce and variable. Cell lines lack physiological relevance. PancreaScale is a proprietary iPSC-derived platform that generates functional human pancreatic microtissues containing beta, alpha, and delta cells in 15 days using a chemically defined small-molecule protocol. Microtissues self-organize into 3D structures mimicking native islet architecture and demonstrate glucose-stimulated insulin secretion (GSIS). The protocol eliminates recombinant growth factors and animal-derived components, reducing cost of goods by over 90% while ensuring batch consistency from a master iPSC bank.Pan-NAM benchmarks PancreaScale against industrial standards defined by a global leader in metabolic drug development, who specified three validation criteria: (1) reproducible production with CV below 15% and Z-factor above 0.5 in 384-well format, (2) physiological insulin secretion response to GLP-1 agonists benchmarked against human islet data, and (3) a T2D disease model with blunted GSIS and proinsulin-to-insulin ratio above 15%. The 9-month project advances PancreaScale from TRL 4 to TRL 5 through three work packages: industrial scale-up, physiological validation, and T2D disease modeling.
Five Letters of Intent from partners spanning large pharma, contract research organizations, and specialized biotech confirm demand across the drug discovery value chain. The FDA Modernization Act 2.0 and EU Directive 2010/63/EU support adoption of validated human-relevant alternatives for metabolic drug screening.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2026-AIC

See all projects funded under this call

Coordinator

STEMX BIO B.V.
Net EU contribution
€ 300 000,00
Address
GALILEIWEG 8
2333 BD Leiden
Netherlands
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data